The Research Roundup provides an overview of the past week’s research from Mayo Medical Laboratories consultants, including featured abstracts and complete list of published studies and reviews.
No Difference between Latiglutenase and Placebo in Reducing Villous Atrophy or Improving Symptoms in Patients with Symptomatic Celiac Disease
Gluten ingestion leads to symptoms and small intestinal mucosal injury in patients with celiac disease. The only option is the strict lifelong exclusion of dietary gluten, which is difficult to accomplish. Mayo Clinic researchers performed a phase 2 study of the ability of latiglutenase, an orally administered mixture of two recombinant gluten-targeting proteases, to reduce mucosal morphometric measures in biopsies from patients with celiac disease. The double-blind, placebo-controlled, dose-ranging study assessed the efficacy and safety of latiglutenase in 494 patients with celiac disease (with moderate or severe symptoms) in North America and Europe. Patients with documented moderate or severe symptoms and villous atrophy were randomly assigned to groups given placebo or 100, 300, 450, 600, or 900 mg latiglutenase daily for 12 or 24 weeks. In modified intent to treat population, there were no differences between latiglutenase and placebo groups in change from baseline in villous height:crypt depth ration, numbers of IELs, or serologic markers of celiac disease. All groups had significant improvements in histologic and symptom scores. According to the results, latiglutenase did not improve histologic and symptom scores when compared to placebo. There were no significant differences in change from baseline between groups. The case was published in Gastroenterology.
Published to PubMed This Week
- Clarifying Immunoglobulin Gene Usage in Systemic and Localized Immunoglobulin Light Chain Amyloidosis by Mass Spectrometry.
- Colonic Transit and Bile Acid Synthesis or Excretion in Patients With Irritable Bowel Syndrome-Diarrhea Without Bile Acid Malabsorption
Clinical Gastroenterology and Hepatology
- Troponin Autoantibodies: From Assay Interferent to Mediator of Cardiotoxicity
- Diagnostic Performance of MR Elastography and Vibration-controlled Transient Elastography in the Detection of Hepatic Fibrosis in Patients with Severe to Morbid Obesity
- Oesophageal Lichen Planus: The Efficacy of Topical Steroid-Based Therapies
Alimentary Pharmacology & Therapeutics
- Cryofibrinogen-Associated Glomerulonephritis
American Journal of Kidney Diseases
- Discontinuing Mycophenolate with Respect to Pregnancy and the Interpretation of Voluntary Registry Results
American Journal of Transplantation
- A Randomized Phase II Trial Comparing Chemoimmunotherapy With or Without Bevacizumab in Previously Untreated Patients with Chronic Lymphocytic Leukemia
- Ixazomib Cardiotoxicity: A Possible Class Effect of Proteasome Inhibitors
American Journal of Hematology
- Clinicopathologic Heterogeneity in FTDP-17 Due to MAPT p.P301L Mutation, Including a Patient with Globular Glial Tauopathy
Neuropathology and Applied Neurobiology
- Outcomes Following Radical Cystectomy for Plasmacytoid Urothelial Carcinoma: Defining the Need for Improved Local Cancer Control
- HLA-DR Polymorphisms Influence in Vivo Responses to Staphylococcal Toxic Shock Syndrome Toxin-1 in a Transgenic Mouse Model
- Pericardiectomy as a Diagnostic and Therapeutic Procedure
BMJ Case Reports